Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
26 hedge funds and large institutions have $23.9M invested in Astria Therapeutics in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
8% more funds holding
Funds holding: 24 → 26 (+2)
0.03% more ownership
Funds ownership: 6.31% → 6.34% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
32% less capital invested
Capital invested by funds: $35.1M → $23.9M (-$11.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WG
Winton Group
London,
United Kingdom
|
+$431K |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$428K |
| 3 |
OC
Oppenheimer & Co
New York
|
+$73.4K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$52.5K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$46.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$208K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$199K |
| 3 |
Millennium Management
New York
|
-$170K |
| 4 |
JP Morgan Chase
New York
|
-$74.4K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$54K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Fidelity Investments
Boston,
Massachusetts
| $1K | +$1.26K | +32 | New |
|
|
27
Millennium Management
New York
| – | -$170K | -3,520 | Closed |
|
|
PAM
28
Panagora Asset Management
Boston,
Massachusetts
| – | -$54K | -1,121 | Closed |
|
29
UBS Group
Zurich,
Switzerland
| – | -$11K | -233 | Closed |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| – | -$6K | -118 | Closed |
|
ATXS Hedge Fund Activity: Q3 2019 in Review
26 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q3 2019, worth a combined $23.9M — down 32% from $35.1M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ATXS positions and 4 closed out — a net gain of 2 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Winton Group, opening a new position worth an estimated $431K. The largest seller was Renaissance Technologies, cutting an estimated $208K.
- 26 institutional investors held Astria Therapeutics (ATXS) as of Q3 2019, up from 24 in Q2 2019.
- Funds reported $23.9M of Astria Therapeutics stock for Q3 2019, down 32% quarter-over-quarter.
- 6 funds opened new Astria Therapeutics positions in Q3 2019 and 4 closed out, a net change of +2 holders.
- The largest Astria Therapeutics buyer in Q3 2019 was Winton Group, an estimated $431K added.
- The largest Astria Therapeutics seller in Q3 2019 was Renaissance Technologies, an estimated $208K sold.
Based on aggregated 13F filings for Q3 2019.